Evorel Patches Explained: Where to Apply Them, Available Doses, and Possible Side Effects

Reading time: 15 minutes
Reading mode:

What Evorel patches are and what they are used for

Evorel is a prescription oestrogen-only transdermal hormone replacement therapy (HRT) patch available in the UK. It contains estradiol, a form of the hormone oestrogen that the body produces naturally, and delivers it through the skin into the bloodstream. This method of delivery is often preferred as it avoids passing the medication through the digestive system first.

A sealed foil pouch containing an Evorel oestrogen patch on a clean surface

The primary licensed use for Evorel is to treat symptoms caused by oestrogen deficiency in women who are experiencing peri-menopause or have reached post-menopause. These symptoms typically include hot flushes and sweating.

Evorel 50, Evorel 75, and Evorel 100 strengths carry an additional licence for the prevention of osteoporosis in postmenopausal women who are at high risk of fractures and for whom other approved osteoporosis medicines are not suitable. Evorel 25 is not licensed for this purpose. This preventive indication is limited; it does not make Evorel a general treatment for osteoporosis or bone health, but rather an option within a specific clinical context where other therapies cannot be used.

Evorel 25, 50, 75 and 100 strengths explained

The numbers on the box-25, 50, 75, and 100-refer to the nominal amount of estradiol, in micrograms, that the patch releases per 24 hours. They do not represent the total quantity of hormone contained within the adhesive layer. The actual content is higher to ensure a steady delivery rate over the wear period. Stronger patches are physically larger, with labelled surface areas of 8, 16, 24, and 32 square centimetres for the respective strengths.

An oestrogen patch applied to the outer thigh below the waist on clean, hairless skin

For managing menopausal symptoms, UK guidance generally recommends starting therapy with the Evorel 50 patch. The strength can be adjusted after the first month based on how well symptoms are controlled and whether there are signs of excessive oestrogen exposure. The goal is to find and maintain the lowest effective dose.

Evorel 100 delivers the maximum labelled dose of 100 micrograms per day. It represents the highest licensed strength in the standard Evorel range, but being the highest available option does not mean it is appropriate for everyone, nor does it indicate that a lower dose is ineffective or unsafe. Dose suitability depends on individual clinical assessment rather than a universal hierarchy of effectiveness.

Readers should not attempt to equate these patch strengths with doses from other delivery methods, such as gels, sprays, or tablets. These systems use different units and absorption profiles, so direct conversion is not possible. Patches should never be cut, combined, or altered to change the dose. Any decision to start, stop, or switch Evorel strength must come from a prescriber based on individual needs and response to treatment.

Where to place an Evorel patch

Correct placement is essential for the patch to adhere properly and deliver oestrogen consistently. Evorel should be applied to clean, dry, cool, and healthy skin located below the waist. The patient leaflet specifically recommends a hairless area, such as the thigh or the buttocks, as suitable sites. These locations generally offer a flat surface that minimises movement and friction during daily activities.

Distinguish between an anatomically acceptable site and one that is practical for long-term wear. Even if a location is technically below the waist, it may be unsuitable if it is subject to constant pressure or rubbing. Areas beneath tight waistbands, elasticated underwear, or restrictive clothing should be avoided, as this friction can loosen the adhesive and reduce effectiveness. Placing the patch on skin with cuts, spots, irritation, or rashes will prevent proper adhesion and may cause further discomfort.

Have you ever applied a hormone replacement therapy patch to your thigh or buttocks?
A person pressing a transdermal patch firmly onto the thigh with the palm of their hand

The application site must also remain free of topical products. Creams, moisturisers, lotions, and talcum powder should not be applied to the chosen area, as these substances can interfere with the adhesive bond. To allow the skin to recover and reduce the risk of local irritation, the patch should not be applied to the exact same spot twice in a row. Rotating application sites within the recommended lower-body regions helps maintain skin integrity throughout treatment.

Do not place the Evorel patch on or near the breasts. The skin in this area is more sensitive, and application here increases the risk of local adverse reactions without providing any benefit to transdermal absorption efficiency.

Test your knowledge with a few quick questions. Choose one answer for each question and see how well you know the topic.

Evorel Patch Basics Quiz

Which statement best describes Evorel Conti compared with standard Evorel?

How to apply, change and dispose of Evorel patches

Proper application ensures consistent hormone delivery and minimises the risk of the patch becoming detached. Each Evorel patch comes in an individually sealed pouch that must be kept intact until ready for use. Open the pouch carefully and remove the patch immediately; delaying application after opening can affect the adhesive properties.

A used hormone patch folded in half with the adhesive sides stuck together for safe disposal

When handling the patch, avoid touching the adhesive surface. Dirt or oils from the skin can compromise the bond between the patch and the body. Once positioned on the prepared site below the waist, press the patch firmly in place using the palm of your hand for at least 10 seconds. Ensure all edges are secure, particularly around any curves or folds in the skin.

Evorel is changed twice weekly on the same two days each week. This schedule creates alternating wear periods of three and four days. Maintaining consistent change days helps establish a routine and ensures stable hormone levels throughout the week.

The patch is waterproof and may remain on during bathing, showering, swimming, or other water-based activities. If the patch begins to lift slightly during these activities, it can usually be pressed back down with dry hands. Do not use tape or additional adhesives to secure a loose patch; if it remains unsecure, follow the guidance for detached patches.

Disposal of used patches requires care to prevent accidental exposure. Remove the old patch and fold it in half so that the adhesive sides stick together. This prevents any residual medication from contacting children or pets who might handle discarded waste. Do not flush Evorel patches down the toilet. Dispose of them in household trash or according to local pharmacy take-back guidelines.

What to do if a patch falls off or a change is missed

Accidents happen, but the response differs depending on whether the patch detaches prematurely or you simply forget to replace it at the scheduled time. It is crucial not to confuse these two scenarios, particularly regarding whether an extra dose should be applied.

If Evorel falls off during the wear period, apply a new patch immediately to restore hormone delivery. Use a different application site within the recommended lower-body areas; do not re-apply the same patch or place the new one on the exact same spot if possible. Keep your original change days unchanged. For example, if you normally change patches on Mondays and Thursdays, continue with that schedule even after applying a replacement mid-week. This prevents over-exposure and maintains the intended release rhythm.

Mild red rash and slight swelling on skin where an oestrogen patch was recently removed

If the detachment occurs shortly after bathing or showering, ensure the skin is thoroughly dried and has returned to a cool temperature before applying the new patch. Applying adhesive to warm or damp skin can prevent proper bonding, leading to further detachment.

Handling a missed change requires a different approach based on timing. If you realize you have forgotten to change your Evorel patch at the scheduled time, remove the old patch and apply a new one as soon as possible. Then, return to your regular schedule for the next change. Do not apply two patches at once to “catch up.”

If it is almost time for your next scheduled change, skip the missed change entirely. Remove the old patch when due and apply a fresh one. This ensures you do not exceed the intended weekly dose. Be aware that delayed or irregular changes can lead to breakthrough bleeding or spotting. While this is generally not harmful, maintaining a consistent schedule helps minimize such interruptions in symptom control.

Common Evorel patch side effects

Side effects from Evorel are common but not inevitable. Clinical trials indicate that adverse reactions occur frequently enough to be noticeable, yet many women tolerate the treatment well without significant disruption. Symptoms generally fall into two categories: local reactions at the application site and systemic effects throughout the body.

Local skin reactions are among the most frequent issues reported. These include rash, itching, redness, or swelling where the patch is placed. Because the adhesive and the hormone itself interact with the skin, some users experience irritation that can range from mild discomfort to a more pronounced inflammatory response. Rotating application sites, as recommended, helps mitigate this risk by giving the skin time to recover between applications.

Systemic side effects mirror those associated with oestrogen exposure elsewhere in the body. Headache is a frequently reported symptom, along with dizziness and breast pain or tenderness. Gastrointestinal issues such as abdominal pain, nausea, and diarrhoea may also occur. Some users experience mood changes, including depressed mood, while others report joint pain or weight increase.

Have you experienced any side effects from using HRT patches?

Breakthrough bleeding or spotting is another common outcome, particularly during the first few months of treatment. This occurs because the uterine lining adjusts to the oestrogen levels. While not dangerous in itself, it can be inconvenient and may prompt a review of the treatment regimen if it persists or becomes heavy.

Distinguish these common effects from serious warning signs. Mild itching, temporary headaches, or occasional spotting are typically manageable and often diminish as the body adjusts. Severe allergic reactions, sudden severe headaches, chest pain, or heavy irregular bleeding require immediate medical attention rather than simple monitoring. Not every woman will experience side effects, and the presence of mild symptoms does not necessarily mean the treatment is unsuitable. Persistent or distressing side effects should be discussed with a healthcare provider to determine if an adjustment in strength, application site, or HRT type is warranted.

Warning signs and longer-term HRT risks

While common side effects like skin irritation or headaches are typically manageable, certain symptoms require immediate medical attention. The Evorel patient information leaflet identifies specific warning signs that suggest serious adverse events, such as blood clots, heart attacks, or strokes. Users should remove the patch and seek prompt medical care if they experience symptoms indicative of these conditions, such as sudden severe headaches, chest pain, difficulty breathing, or swelling and pain in one leg.

Two different hormone patches shown side by side, one oestrogen-only and one combined oestrogen and progestogen

Other urgent symptoms include facial or throat swelling accompanied by difficulty swallowing or breathing, which may signal a severe allergic reaction. Jaundice or signs of liver problems, such as yellowing of the skin or eyes, also require immediate assessment. A first-time migraine-type headache or a substantial increase in blood pressure warrants urgent review. Long, heavy, or irregular bleeding that has not previously occurred can indicate endometrial disease and should not be ignored.

Beyond these acute warning signs, HRT use is associated with certain longer-term risks that are considered during the initial prescribing assessment and periodic reviews. Clinical studies have reported higher rates of breast cancer, endometrial hyperplasia or cancer, and ovarian cancer among women using hormone replacement therapy compared to non-users. The risk of venous thromboembolism (blood clots), heart disease, and stroke is also elevated with HRT use.

For oestrogen-only therapies like standard Evorel, the risk profile differs from combined HRT products. These statements describe relative risks observed in study populations and do not provide an individual's absolute risk. Risk varies based on age, duration of treatment, and personal medical history. For instance, some studies suggest an increased risk of probable dementia when HRT is started after the age of 65.

Transdermal oestrogen delivery does not eliminate all cardiovascular or thrombotic risks associated with hormone therapy. While the patch bypasses the digestive system, it still delivers oestrogen into the circulation, which can influence clotting factors and other physiological processes. Understanding these longer-term risks is essential for ongoing safety, but they should be weighed against the benefits of symptom relief and quality of life improvements in discussion with a healthcare provider.

Evorel versus Evorel Conti

The most common point of confusion regarding this product range is distinguishing between standard Evorel and Evorel Conti. Although they share a brand name, they are fundamentally different therapies designed for different stages of menopause and different uterine statuses.

Standard Evorel contains estradiol alone. It is an oestrogen-only patch intended to replenish declining oestrogen levels. Because it provides only oestrogen, it requires a separate progestogen treatment if the user still has her uterus, to protect the endometrial lining from overgrowth.

Evorel Conti is a continuous combined hormone replacement therapy. It delivers both estradiol and norethisterone acetate, a form of progestogen, through a single patch. Each Evorel Conti patch nominally releases 50 micrograms of estradiol and 170 micrograms of norethisterone acetate per 24 hours. Like standard Evorel, it is applied twice weekly, but unlike the cyclical regimens used with some other combined therapies, Conti is worn continuously without a break for withdrawal bleeding.

This distinction determines who each product is licensed for. Standard Evorel can be used by both premenopausal women transitioning through peri-menopause and postmenopausal women (who may or may not have had a hysterectomy). Evorel Conti is licensed specifically for postmenopausal women who are more than six months after their final period-defined in the product label as 18 months since the last natural period. It is not suitable for women who are still having irregular periods or who require cyclical bleeding patterns, as the continuous progestogen component is designed to prevent such bleeding rather than induce it.

Because Evorel Conti contains a progestogen, its side-effect profile differs from standard Evorel. Clinical trials for Evorel Conti report application-site reactions, menstrual disorders (though typically amenorrhoea or spotting in this context), headache, and breast pain as common adverse events occurring in at least 5% of users. These progestogen-related effects, such as mood changes or bloating, are not inherent to oestrogen-only Evorel. One cannot assume that the side effects experienced on one product will be identical on the other.

Neither standard Evorel nor Evorel Conti replaces the need for a separate progestogen if indicated. Standard Evorel must be paired with an additional progestogen for women with a uterus. Evorel Conti already contains it, so no additional progestogen should be taken while using this specific patch. Confusing the two products can lead to inappropriate dosing or unnecessary duplication of hormones. Any choice between oestrogen-only and continuous combined therapy depends on menstrual history and uterine status, determined by a healthcare professional.

Who should not use Evorel or needs additional review

Evorel is contraindicated for certain individuals due to the potential for serious adverse outcomes. A prescriber must verify that a patient does not have any of the following conditions before initiating treatment: current, previous, or suspected breast cancer; known or suspected oestrogen-dependent malignancy; unexplained genital bleeding; or untreated endometrial hyperplasia.

Further contraindications include a history of venous thromboembolism (blood clots), known thrombophilia (conditions that predispose to clotting), and active or recent arterial thromboembolic events such as stroke, angina, or myocardial infarction. Acute liver disease, previous liver disease accompanied by abnormal liver function tests, hypersensitivity to any ingredient in the patch, and porphyria also prohibit the use of Evorel. These restrictions are absolute; treatment should not be started if any apply.

For women with other medical conditions, a more cautious approach is required. While these issues do not automatically rule out HRT, they necessitate closer medical supervision and periodic benefit-risk reviews. Conditions that warrant additional scrutiny include fibroids or endometriosis, risk factors for thromboembolism or oestrogen-sensitive cancers, hypertension, liver disorders, diabetes, gallstones, migraine or severe headaches, systemic lupus erythematosus, epilepsy, asthma, high triglycerides, and cardiac or renal fluid retention.

In these cases, the prescribing clinician must monitor the patient more closely to ensure that Evorel remains safe. These precautions are not equivalent to contraindications; rather, they indicate that treatment may be possible but requires careful management. Individuals with any of these conditions should discuss their specific risks with their healthcare provider to determine if Evorel is appropriate for them. Regular reviews allow the prescriber to adjust treatment or switch therapies if side effects emerge or new health issues develop.

Progestogen, contraception, pregnancy and breastfeeding

The requirement for progestogen alongside Evorel depends entirely on the status of the uterus. Evorel is an oestrogen-only patch. For a woman who still has her uterus in situ, unopposed oestrogen can cause the endometrial lining to thicken abnormally, increasing the risk of endometrial hyperplasia or cancer. To prevent these adverse effects, the UK summary of product characteristics states that a progestogen should normally be added. An approved progestogen must be prescribed and taken for at least 12-14 days in every monthly or 28-day cycle. The specific product and regimen must be determined by a prescriber; readers should not infer a suitable progestogen choice or schedule from general information. There is a relevant exception for women who have had a hysterectomy, particularly those with a previous history of endometriosis, where the need for additional progestogen differs.

Do you take a progestogen alongside your oestrogen-only HRT?

Evorel is not a contraceptive. It does not suppress ovulation in peri-menopausal women who may still be fertile. Women of childbearing potential using Evorel must use non-hormonal contraception to prevent pregnancy. The product is not indicated during pregnancy or lactation. If pregnancy occurs while using Evorel, treatment should be withdrawn immediately and a healthcare provider consulted. There is no evidence supporting the use of Evorel for breast milk production or in breastfeeding women; therefore, it should not be used during this period.

Menopause: diagnosis and management

Source organization: National Institute for Health and Care Excellence

Hormone replacement therapy (HRT)

Source organization: NHS

Questions & comments

Reader question

Do I need to add a progestogen if I've had a hysterectomy?

Editor reply

Evorel contains only estrogen, and a progestogen is normally added only when a uterus is present to protect the endometrium. If you have had a hysterectomy and no uterus remains, you typically do not need a progestogen with Evorel, unless your clinician advises otherwise (for example, if you have a history of endometriosis).

Please do not include passwords, medical record numbers, insurance information, financial information, precise addresses, or other confidential or directly identifying information in your message.